ALETA-004

About Aleta Biotherapeutics

Aleta Biotherapeutics is pioneering a novel approach to overcome limitations of CAR T-cell therapies, particularly antigen escape and relapse. Its proprietary CAR T Engager (CTE) proteins are off-the-shelf biologics that bind to cancer cells and 're-target' them for destruction by a patient's existing CAR T cells, effectively boosting antigen density and preventing resistance. With its lead asset, ALETA-001, in a Phase I/II trial supported by Cancer Research UK and holding key regulatory designations, the company is initially targeting the significant unmet need in lymphoma and myeloma, with a preclinical pipeline extending into AML and solid tumors. Aleta is a private company leveraging a capital-efficient, asset-centric model to advance its platform.

Therapeutic Areas

Other Acute Myeloid Leukemia (AML) Drugs